Full-Time

Senior Scientist – Principal Scientist

Computational Chemistry

Superluminal Medicines

Superluminal Medicines

51-200 employees

ML-driven design of candidate small molecules

No salary listed

Boston, MA, USA

In Person

PhD

Category
AI & Machine Learning (1)
Required Skills
Scikit-learn
Python
PyTorch
Machine Learning
AWS
Pandas
NumPy
Linux/Unix

Get referred to Superluminal Medicines

See people who can refer or advise you

Requirements
  • Ph.D. in Computational Chemistry, Biophysics, or a related field
  • 1-3+ years of experience in a biotech or pharma setting performing computational support for small molecule drug discovery
  • Advanced knowledge of physics-based and machine learning computational chemistry packages including knowing when and how to deploy various tools for maximum project impact
  • Exceptional ability to communicate the "why" behind a design to a diverse scientific audience
  • Design experience working in concert with medicinal chemistry teams to design synthesizable compounds that efficiently work towards defined goals of activity, affinity, selectivity, properties, etc
  • A proven track record for innovation in structure-based small molecule drug discovery including developing and validating new workflows and techniques or expansions of existing ones
  • Expert level use of structure-based small molecule drug discovery software tools including protein preparation, docking, Free Energy Perturbation, quantum mechanics, conformer selection (Schrodinger suite, OpenEye, MOE, etc)
  • Ability to work directly in a Linux-based environment
  • Familiarity with cloud computing infrastructure (AWS, Google Cloud Storage) is a plus
  • Python scripting and prototyping experience including knowledge of key packages (RDKit, scikit-learn, numpy, pandas, pytorch, etc)
Responsibilities
  • Integrate physics-based simulations with ML predictions to achieve the quantitative accuracy required to prioritize compounds for synthesis
  • Collaborate with a team of interdisciplinary scientists to develop actionable hypotheses and design computational experiments
  • Design and prioritize chemical matter specifically aimed at hitting key program milestones, such as establishing in vivo Project Endpoints or Proof of Concept, achieving selectivity windows, or optimizing ADMET profiles for candidate selection
  • Develop, validate and deploy computational workflows to optimize the Design-Make-Test-Analyze cycles and address gaps
Desired Qualifications
  • Experience working with structural biology teams to extract the most information possible from cryo-electron microscopy and X-ray crystallography experiments and using this to accelerate programs using structure-based drug discovery techniques
  • Proven experience using machine learning to scale physics-based insights, specifically in the context of large-scale virtual screening or free energy perturbation-guided lead optimization
  • A proven track record for innovation in structure-based small molecule drug discovery including developing and validating new workflows and techniques or expansions of existing ones
Superluminal Medicines

Superluminal Medicines

View

Superluminal Medicines develops small-molecule drug discovery solutions by combining deep biology, chemistry, and machine learning. It creates candidate-ready compounds with high speed and accuracy, using a proprietary big data platform and predictive design models to model protein shapes and design selective compounds that induce precise structural changes for therapeutic effects. The company collaborates with pharmaceutical and biotech firms, licensing its technology and pursuing milestone-based payments, rather than selling products outright. This partnership-centric model helps clients accelerate their drug discovery programs in a highly competitive market. The company aims to shorten the path from target to clinical candidate by delivering well-characterized, selective small molecules efficiently.

Company Size

51-200

Company Stage

Series A

Total Funding

$153M

Headquarters

Boston, Massachusetts

Founded

2023

Get referred to Superluminal Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lilly's February 2026 update reaffirmed up to $1.3B in payments.
  • Superluminal expects an IND submission in late 2026 for obesity.
  • RA Capital, Insight, NVentures, Catalio, and Lilly funded the $120M Series A.

What critics are saying

  • Lilly gets exclusive rights, so Superluminal loses downstream economics.
  • The lead obesity asset still needs 2026 human data after IND filing.
  • A failed MC4R program would crush platform credibility and future partnering.

What makes Superluminal Medicines unique

  • Superluminal combines protein dynamics, structural biology, and ML on GPCRs.
  • Lilly backed the 2024 Series A and signed a 2025 $1.3B pact.
  • Its lead MC4R obesity program entered IND-enabling studies in July 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Parental Leave

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Tuition Reimbursement

Meal Benefits

Commuter Benefits

Pet Insurance

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

31%

1 year growth

31%

2 year growth

31%
The Pharma Letter
Aug 15th, 2025
Lilly and Superluminal work on GPCR drugs for cardiometabolic diseases

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity.

Fierce Biotech
Aug 14th, 2025
Superluminal secures $1.3B pact with backer Lilly to develop cardiometabolic, obesity drugs

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. | Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.

BioWorld
Aug 14th, 2025
Superluminal, Lilly in $1.3B Deal

Superluminal Medicines Inc. has entered a collaboration with Eli Lilly and Co. in a deal worth up to $1.3 billion. The partnership aims to develop therapies for cardiometabolic diseases and obesity by targeting undisclosed G protein-coupled receptors. The deal includes up-front and near-term investments, an equity investment, development and commercial milestones, and tiered royalties on net sales.

BioWorld
Aug 14th, 2025
Superluminal joins a $1.3B deal with series A backer Lilly

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets.

FinSMEs
Sep 9th, 2024
Superluminal Medicines Closes $120M Series A Funding

Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding